title: [Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
authors.affiliation: Diagnostic and Therapeutic Center of Children's Blood Disease, Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Guo
authors.forename: Tian-Feng
authors.initials: TF
authors.lastname: Liu
authors.forename: Wen-Yu
authors.initials: WY
authors.lastname: Yang
authors.forename: Shu-Chun
authors.initials: SC
authors.lastname: Wang
authors.forename: Min
authors.initials: M
authors.lastname: Ruan
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Chen
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: Yao
authors.initials: Y
authors.lastname: Zou
authors.forename: Xiao-Fan
authors.initials: XF
authors.lastname: Zhu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002648:Child; D000069439:Dasatinib; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib